-
Henan Grave Carved with Herbal Prescriptions Draws Hundreds of Visitors Daily
-
Masdar Completes $950M Lockhart Solar and Storage Project in California
-
USMNT Coaching Search: Guardiola, Cherundolo, and Others Named as Pochettino Replacements
-
Mansa’s AI Microdrama Sparks Debate Over Black Representation in Hollywood
-
SDF Intelligence Unit Avoided Classifying Civilian Data as Public Records
-
Microsoft Outage Disrupts Outlook and Teams for Hours Globally
-
Inflation Breach and Bond Yields Spark Rate Hike Fears for December
-
RSC’s ‘Julius Caesar’ Reimagined in Women’s Prison Setting for School Tour
-
Documentary Reveals How Screams Exposed Alleged Camgirl Exploitation Ring
-
Korea Reviews GLP-1 Vision Loss Warnings Following US FDA Action
-
Road Access Completed Drill Program to Begin
-
ACCESS Newswire Continues to Repurchase its Shares
-
Greenwich LifeSciences Interview to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
-
Jaguar Health to Hold Investor Webcast November 17 Regarding Q3 2026 Financials & Corporate Updates
-
Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates
-
Does IRS Debt Expire? Clear Start Tax Explains the 10-Year Collection Statute and What Quietly Resets It
-
GameSquare's Hatchet Publishes TikTok Live for Gaming in H1 2026 Report
-
Arrive AI Reports Third Quarter 2026 Results Highlighted by Revenue Growth and Expanded Partnerships
-
Digi Power X Reports Q3 2026 Revenue Up 85% and AI Revenue Up Over 400% Compared to Q2
-
Mako Mining Reports Q3 2026 Financial Results, Including Adjusted EBITDA(1) of US$30.3 million and EPS of US$0.19/share
-
eXoZymes to Host Third Quarter 2026 update Conference Call on Thursday, November 19, 2026
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 13
-
How Families Plan and Save for Holiday Travel
-
Vulcan Minerals Inc. - Review and Update on Affiliated Company Atlas Salt Inc.
-
Sparta Capital Ltd. Announces Application to the Ontario Securities Commission to Become a Reporting Issuer in Ontario
-
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2026
-
Rifstone Capital LLC Advances Institutional Research Platform with Expanded Global Allocation Framework
-
SMX Puts American Innovation to Work in the New Era of Artificial Intelligence
-
Sekur Private Data Raises SekurOne Price 25% to US$3,750 Per Year
-
Foundation Software Explores How Contractors Can Prepare for the AI-Driven Construction Boom
-
Trustpoint Xposure Launches Program to Help Startup Founders Check How AI Search Platforms Describe Their Companies
-
DataMEDS AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides Business Update
-
MARS Energy Group Adds Jigar Shah to Advisory Board to Accelerate Battery Storage Growth
-
The Epomaker Alice40 Brings Mahjong Sound and Sunset Style to Ergonomic Typing
-
SMX Brings American Ingenuity to the Next Frontier of Artificial Intelligence
-
Jane Maciver Joins Fragrance Creators Board
-
Below Deck alumnus João Franco and brother arrested after fatal Turkey fight
-
Ole Miss inquiry expands after video and monkey-noise allegations
-
General Hospital actor Randall England dies at 75
-
Argentina Inflation Rises to 2.2% in October Amid Core Price Decline
-
Bunnie XO artwork taken down from Jelly Roll’s Nashville bar
-
London museum removes Russell Brand hair exhibit after rape conviction
-
NRC Approves Construction of Advanced Nuclear Reactors at Texas Petrochemical Site
-
Arlington sentinel rebukes Pete Hegseth entourage for laughter near memorial
-
Yella Beezy sentenced to life for arranging rapper Mo3’s murder
-
Kylie Jenner employee describes closet ordeal and pepper-spray incident
-
Xi Jinping Urges Unity and Reunification at Sun Yat-sen Anniversary
PathPresenter Partners with Leading Global Cancer Center to Integrate AI Module for Oncology Research
"DeepLIIF" algorithm enhances accuracy, reproducibility, and efficiency in pathology, providing a cost-effective solution for advanced biomarker analysis
MONTVILLE, NJ / ACCESS Newswire / March 4, 2025 / PathPresenter, a leader in digital pathology workflow software, is pleased to announce that it is collaborating with Memorial Sloan Kettering Cancer Center (MSK), one of the world's foremost oncology institutes, to integrate the PathPresenter platform with DeepLIIF, a new AI module for oncology research developed at MSK.
DeepLIIF was created by Dr. Saad Nadeem, Assistant Professor and Director of the Nadeem Lab at MSK, in collaboration with Dr. Travis J. Hollmann, who formerly served as Director of Immunomorphology Platforms and Associate Attending Pathologist at MSK. It is a deep-learning algorithm that transforms standard immunohistochemistry (IHC) images into virtual high-resolution multiplex immunofluorescence (IF) images, enabling automated cell segmentation and precise quantification. This approach enhances accuracy, reproducibility, and efficiency in pathology, providing a cost-effective solution for advanced biomarker analysis.
By integrating DeepLIIF into the Pathpresenter image management system, PathPresenter expands access to MSK's powerful AI tools, enabling pathologists worldwide to analyze complex pathology images in a research context more efficiently and accurately.
"We applaud MSK's leadership in continuously advancing the field of digital pathology," said Dr. Cory Batenchuk, SVP of Operations at PathPresenter. "Dr. Nadeem's innovation with DeepLIIF represents a significant advancement in our field and we're delighted to give more pathologists the opportunity to leverage this technology in a research context through the global reach of our platform."
"DeepLIIF is a novel virtual staining AI algorithm deployed at MSK, following rigorous validation and single-site regulatory approval," said Dr. Nadeem. "DeepLIIF allows more accurate cellular phenotyping with whole-cell segmentation and is more sensitive to picking out low and ultra-low IHC DAB expression due to the higher dynamic range in co-registered IF images during training. We are excited to collaborate with PathPresenter to extend our reach while expanding our offerings to more complex markers such as PD-L1 and HER2. Working with PathPresenter, we are hoping to follow the same validation and single-site approval process where applicable for clinical deployment while allowing research use by default."
This collaboration builds upon MSK's experience and familiarity with PathPresenter during the past five years. More than 150 pathologists within the institution currently use MSK's customized PathPresenter installation for digital pathology education and research.
DeepLIIF becomes the latest AI application to be integrated into PathPresenter's vendor-agnostic platform, joining solutions from industry leaders such as Paige, IBEX, 4D Path and MindPeak. With its secure, scalable architecture, PathPresenter offers AI developers a rapid, proven path to deploy their models while providing users with a powerful, consistent workflow for accessing multiple AI solutions.
About PathPresenter
PathPresenter is an enterprise image management and workflow platform for digital pathology. We are on a mission to democratize access to the world's pathology knowledge by connecting pathologists to the vast expertise of their colleagues globally and providing a practical platform to access and use best-in-class AI models. Founded by dermatopathologist and digital pathology pioneer Dr. Rajendra Singh, PathPresenter's secure, scalable, vendor-agnostic enterprise pathology workflow software has been adopted by tier one medical institutions for clinical care, education, and research, and the company has built a thriving community of tens of thousands of users around the world to easily view and share digital pathology images and knowledge. Learn more at https://www.pathpresenter.com.
Contact Details
PathPresenter
Neil Humphrey, VP Marketing
+1 519 498 3402
[email protected]
The PathPresenter Clinical Viewer is a digital pathology image viewing and management software. It is approved for research use only and has not been cleared by the FDA as a medical device. It is the responsibility of a qualified pathologist to employ appropriate procedures and safeguards to assure the validity of the interpretation of images obtained using this device. Pathologists should exercise professional judgment in each clinical situation and examine the glass slides by conventional microscopy if there is doubt about the ability to accurately render an interpretation using this device alone.
DeepLIIF is for research use only.
SOURCE: PathPresenter
View the original press release on ACCESS Newswire
T.Sanchez--AT